The organic, inorganic, and residual solvent impurity sources in pharmacological compounds have been divided into categories by the International Council for Harmonization. The pharmaceutical sector faces a regulatory hurdle since the organic contaminants could be genotoxins. The detection and method development also a validation of organic contaminants produced during the chromatographic separation of a teriflunomide is the main goal of this work. The impurity profile research was carried out using a diode array detector and reverse phase-high performance liquid chromatography. At a column temperature of 25°C, the C18 YMC-Pack ODS column was successfully achieved through gradient separation. As the mobile phase, acetonitrile and 0.015 M potassium dihydrogen phosphate with a pH of 3.5 were employed. A 210 nm detector wavelength and 1.0 ml/minute flow rate were adopted. Six process-related impurities were successfully separated using the validated analytical method, with resolution and retention times under 35 minutes. Teriflunomide, Teriflunomide stage-1, and Impurity-D have established analytical techniques with ranges of 0.066–3.262, 0.035–1.880, and 0.025–1.255 μg/ml, respectively. Teriflunomide, Teriflunomide stage-1, and impurity-D have respective limits of detection and limit of quantification values of 0.0037 and 0.0096, 0.0016 and 0.0051, and 0.0011 and 0.0033 μg/ml. The confirmed analytical approach can effectively identify any manufacturing process impurities.
Koppisetty BRB, Yejella RP, Pawar AKM, Yarraguntla SR, Kollabathula VR, Dadi V, Naidu CG. Development of a validated RP-HPLC assay method for quantitative separation of Teriflunomide and its process related impurities in bulk drugs. J Appl Pharm Sci, 2023; 13(Suppl 1):028–033. https://doi.org/10.7324/JAPS.2023.129159
European Medicines Agency. European Public Assessment Report. AUBAGIO (International non-proprietary name: Teriflunomide), Procedure No. EMEA/H/C/002514/0000. European Medicines Agency, EMA/529295/2013, 2013. | |
ICH. Validation of analytical procedures, International Conference on Harmonization, IFPMA, Geneva, Switzerland, 1994. | |
Lakshmi GT, Srinivasa RY, Varaprasadrao K, Hemant KT. RP-HPLC method for estimation of atomoxetine hydrochloride in bulk and pharmaceutical dosage form. Res J Pharm Biol Chem Sci, 2015; 2:1208-14. | |
Nukendra PN, Venkatanadh R, Srinivasu N. Quality-by-design-based development and validation of a stability-indicating UPLC method for quantification of teriflunomide in the presence of degradation products and its application to in-vitro dissolution. J Liq Chromatogr Relat Technol, 2017; 40(10):517-27. https://doi.org/10.1080/10826076.2017.1330211 | |
Pandey S, Mahtab A, Singh A, Ahmad FJ, Aqil M, Talegaonkar S. Development and validation of stability indicating reversed-phase liquid chromatographic method for simultaneous quantification of methotrexate and teriflunomide in nanoparticles and marketed formulation. Biomed Chromatogr, 2018; 32(12):e4372. https://doi.org/10.1002/bmc.4372 | |
Parekh JM, Vaghela RN, Sutariya DK, Sanyal M, Yadav M, Shrivastav PS. Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2010; 878(24):2217-5. https://doi.org/10.1016/j.jchromb.2010.06.028 | |
Rakhila H, Rozek T, Hopkins A, Proudman S, Cleland L, James M, Wiese M. Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS. J Pharm Biomed Anal, 2011; 55(2):325-31. https://doi.org/10.1016/j.jpba.2011.01.034 | |
Rule GS, Rockwood AL, Johnson-Davis KL. LC-MS/MS Method for the quantification of the leflunomide metabolite, teriflunomide, in human serum/plasma. Methods Mol Biol, 2019; 1872:75-83. https://doi.org/10.1007/978-1-4939-8823-5_8 | |
Srinivasa YR, Gandi P, Varaprasadrao K, Hemant KT. Development and validation of visible spectrophotometric method for the estimation of zaltoprofen in tablet dosage form. Der Pharm Lett, 2015; 7(1):196-201. | |
Suneetha A, Raja RK. Comparison of LC-UV and LC-MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study. Biomed Chromatogr, 2016; 30(9):1371-7. https://doi.org/10.1002/bmc.3694 | |
Vidyadhara, Suryadevara, Srinivasa RY, Ramu A, Sasidhar RL, Ramya JA. Method development and validation for the simultaneous estimation of cinitapride and pantoprazole in solid dosage forms by RP-HPLC. Orient J Chem, 2013; 29(3):1213. https://doi.org/10.13005/ojc/290355 | |
https://pubchem.ncbi.nlm.nih.gov/compound/Teriflunomide (Accessed 17 December 2022). | |
h t t p s : / / p u b c h e m . n c b i . n l m . n i h . g o v / c o m p o u n d / 5 - Methylisoxazole-4-carboxylic-acid (Accessed 17 December 2022). | |
https://pubchem.ncbi.nlm.nih.gov/compound/21912858 (Accessed 17 December 2022). | |
https://pubchem.ncbi.nlm.nih.gov/compound/5-Methyl-N-_4- methylphenyl_isoxazole-4-carboxamide (Accessed 17 December 2022). | |
https://pubchem.ncbi.nlm.nih.gov/compound/4-_ Trifluoromethyl_aniline (Accessed 17 December 2022) |
Year
Month